| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Coronarin D targets the NF-kappaB (NF-κB) activation pathway, a key signaling pathway involved in inflammation, cell survival, and immune responses. By inhibiting NF-κB activation, Coronarin D reduces the expression of pro-inflammatory genes, inhibits cell invasion, suppresses osteoclastogenesis, and promotes apoptosis. The compound's mechanism of action involves modulation of inflammatory and cell survival signaling pathways.
|
|---|---|
| ln Vitro |
Coronarin D inhibits the NF-kappaB activation pathway, which leads to inhibition of inflammation, invasion, and osteoclastogenesis, as well as potentiation of apoptosis. The compound shows promising antifungal activity against C. albicans in vitro. It also exhibits anti-inflammatory, antioxidant, and anticancer properties. Coronarin D can be used in combination with antibiotic drugs to combat infectious diseases.
|
| ln Vivo |
In vivo activity data for Coronarin D are not extensively detailed. As an inhibitor of NF-κB activation, it is expected to exhibit anti-inflammatory and anticancer activities in vivo. The compound's anti-inflammatory, antioxidant, and anticancer properties suggest potential for in vivo efficacy. Specific in vivo efficacy studies and animal model data are not specified in the public domain. The compound is intended for research use only.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for Coronarin D typically involves measuring its inhibition of NF-κB activation. Cells are treated with varying concentrations of Coronarin D (typically 0.1-100 µM) and stimulated with activators such as TNF-α or LPS. NF-κB activation is assessed by measuring NF-κB DNA binding activity using EMSA or by measuring the expression of NF-κB target genes by qPCR. The compound is dissolved in DMSO and diluted in cell culture medium.
|
| Cell Assay |
In vitro cellular assays for Coronarin D typically involve treating various cell lines with the compound at concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or CellTiter-Glo assays. Anti-inflammatory activity is assessed by measuring cytokine production (such as TNF-α, IL-6, and IL-1β) by ELISA. Antifungal activity is assessed by broth microdilution methods against C. albicans. The compound is dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for Coronarin D are not extensively documented. For potential in vivo applications, the compound could be administered to mice via oral gavage or intraperitoneal injection at doses determined from preliminary studies. Inflammation models, tumor xenograft models, or infection models could be used to evaluate efficacy. Inflammatory markers, tumor growth, and fungal burden are assessed. The compound's pharmacokinetics and pharmacodynamics would be evaluated in these models.
|
| ADME/Pharmacokinetics |
Coronarin D has a molecular weight of 318.45 g/mol and formula C20H30O3. It is a liquid at 20°C. Purity is typically ≥95%. The compound is soluble in organic solvents such as DMSO and ethanol. Recommended storage is at -20°C. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination.
|
| Toxicity/Toxicokinetics |
Coronarin D is intended for research use only and is not approved for human therapeutic applications. As an NF-κB inhibitor, the compound may affect normal inflammatory and immune responses, which could contribute to potential toxicity. Standard preclinical toxicity assessments would include acute toxicity studies in rodents, repeated-dose toxicity studies, and assessment of off-target effects. Appropriate safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
Reports have indicated that ginger flower (Hedychium coronarium) contains coronin D, and relevant data is available for reference.
Coronarin D (CAS 119188-37-3) is a cytotoxic labdane-type diterpene compound with a molecular weight of 318.45 g/mol and formula C20H30O3. It inhibits the NF-kappaB activation pathway, leading to inhibition of inflammation, invasion, and osteoclastogenesis, as well as potentiation of apoptosis. Coronarin D shows antifungal activity against C. albicans and has anti-inflammatory, antioxidant, and anticancer properties. It is also known as 3-[2-(5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl)ethylidene]-5-hydroxyoxolan-2-one. |
| Molecular Formula |
C20H30O3
|
|---|---|
| Molecular Weight |
318.45000
|
| Exact Mass |
318.219
|
| CAS # |
119188-37-3
|
| PubChem CID |
52947373
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
466.7±45.0 °C at 760 mmHg
|
| Flash Point |
186.9±21.5 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.535
|
| LogP |
4.99
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
545
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@]12CCCC([C@@H]1CCC(=C)[C@@H]2C/C=C\3/CC(OC3=O)O)(C)C
|
| InChi Key |
DYYYQLXAGIXUGM-FKKKBMQXSA-N
|
| InChi Code |
InChI=1S/C20H30O3/c1-13-6-9-16-19(2,3)10-5-11-20(16,4)15(13)8-7-14-12-17(21)23-18(14)22/h7,15-17,21H,1,5-6,8-12H2,2-4H3/b14-7-/t15-,16-,17?,20+/m0/s1
|
| Chemical Name |
(3Z)-3-[2-[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-5-hydroxyoxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1402 mL | 15.7011 mL | 31.4021 mL | |
| 5 mM | 0.6280 mL | 3.1402 mL | 6.2804 mL | |
| 10 mM | 0.3140 mL | 1.5701 mL | 3.1402 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
